<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Protein expression levels in immunohistochemistry and molecular biomarkers have been reported for their ability to predict recurrence, progression, development of metastases, and patient survival. The molecular features in low- and high-grade prostate cancer can differ and influence treatment decision and prognosis. The objective of the current study was to compare the expression of exosomal biomarkers CD63 and mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) by immunohistochemistry (IHC) in tissue of patients with prostate cancer and benign hyperplasia. Altogether, 62 patients with prostate acinar adenocarcinoma and 20 patients with prostate benign hyperplasia were enrolled in this retrospective study. CD63, MSH2, MSH6, MLH1, and PMS2 expression was analysed by immunohistochemistry. The obtained results showed that CD63 expression was significantly higher in patients with Grade III–V prostate cancer compared to Grade I–II, respectively; 2.23 (1–3) vs 0.92 (0–2) score, p = 0.001. In addition, a significant positive correlation between CD63 expression and grade groups was revealed (Rho = +0.54; p &lt; 0.0001). Furthermore, progression-free survival was significantly higher in patients with low CD63 expression, compared to high CD63 expression (p = 0.0007). MMR expression was absent in 14 patients (four patients with Grade I–II cancer and 10 patients with Grade III–cancer). MMR was present in all cases of benign prostate hyperplasia (mild to moderate staining). The conclusion was that high grade prostate cancer (Grade groups III–V) was characterised by increased CD63 expression, which correlated with progression-free survival.</p>
</abstract>

Protein expression levels in immunohistochemistry and molecular biomarkers have been reported for their ability to predict recurrence, progression, development of metastases, and patient survival. The molecular features in low- and high-grade prostate cancer can differ and influence treatment decision and prognosis. The objective of the current study was to compare the expression of exosomal biomarkers CD63 and mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) by immunohistochemistry (IHC) in tissue of patients with prostate cancer and benign hyperplasia. Altogether, 62 patients with prostate acinar adenocarcinoma and 20 patients with prostate benign hyperplasia were enrolled in this retrospective study. CD63, MSH2, MSH6, MLH1, and PMS2 expression was analysed by immunohistochemistry. The obtained results showed that CD63 expression was significantly higher in patients with Grade III–V prostate cancer compared to Grade I–II, respectively; 2.23 (1–3) vs 0.92 (0–2) score, p = 0.001. In addition, a significant positive correlation between CD63 expression and grade groups was revealed (Rho = +0.54; p < 0.0001). Furthermore, progression-free survival was significantly higher in patients with low CD63 expression, compared to high CD63 expression (p = 0.0007). MMR expression was absent in 14 patients (four patients with Grade I–II cancer and 10 patients with Grade III–cancer). MMR was present in all cases of benign prostate hyperplasia (mild to moderate staining). The conclusion was that high grade prostate cancer (Grade groups III–V) was characterised by increased CD63 expression, which correlated with progression-free survival.

CD63 and Dna Mismatch Repair Protein Expression in Prostate Cancer

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"CD63 and Dna Mismatch Repair Protein Expression in Prostate Cancer"}

Protein expression levels in immunohistochemistry and molecular biomarkers have been reported for their ability to predict recurrence, progression, development...

CD63 and Dna Mismatch Repair Protein Expression in Prostate Cancer

Publicado en línea: 22 jul 2021

Páginas: 180 - 185

Recibido: 02 nov 2020

Aceptado: 14 ene 2021

DOI: https://doi.org/10.2478/prolas-2021-0027

Palabras clave
CD63 exosomal biomarker, mismatch repair protein biomarkers, mismatch repair pathway deficiency, immunohistochemistry, prostate acinar adenocarcinoma, benign prostate hyperplasia

© 2020 Kristofs Folkmanis et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

CD63 and Dna Mismatch Repair Protein Expression in Prostate Cancer

Publicado en línea: 22 jul 2021

Páginas: 180 - 185

Recibido: 02 nov 2020

Aceptado: 14 ene 2021

DOI: https://doi.org/10.2478/prolas-2021-0027

Palabras claveCD63 exosomal biomarker, mismatch repair protein biomarkers, mismatch repair pathway deficiency, immunohistochemistry, prostate acinar adenocarcinoma, benign prostate hyperplasia

© 2020 Kristofs Folkmanis et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Palabras clave
CD63 exosomal biomarker, mismatch repair protein biomarkers, mismatch repair pathway deficiency, immunohistochemistry, prostate acinar adenocarcinoma, benign prostate hyperplasia